613 related articles for article (PubMed ID: 25261844)
21. Changes of choroidal thickness after treatment for diabetic retinopathy.
Lee SH; Kim J; Chung H; Kim HC
Curr Eye Res; 2014 Jul; 39(7):736-44. PubMed ID: 24502275
[TBL] [Abstract][Full Text] [Related]
22. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
23. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
24. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.
Kim M; Cho YJ; Lee CH; Lee SC
Eye (Lond); 2016 May; 30(5):718-25. PubMed ID: 26939558
[TBL] [Abstract][Full Text] [Related]
25. CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.
Nourinia R; Ahmadieh H; Nekoei E; Malekifar P; Tofighi Z
Retina; 2018 May; 38(5):970-975. PubMed ID: 28426622
[TBL] [Abstract][Full Text] [Related]
26. Functional and anatomic response of the retina and the choroid to intravitreal bevacizumab for macular edema.
Forte R; Cennamo G; Breve MA; Vecchio EC; de Crecchio G
J Ocul Pharmacol Ther; 2012 Feb; 28(1):69-75. PubMed ID: 22059904
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
Sophie R; Lu N; Campochiaro PA
Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
[TBL] [Abstract][Full Text] [Related]
28. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
Domalpally A; Ip MS; Ehrlich JS
Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
[TBL] [Abstract][Full Text] [Related]
29. Choroidal thickness in diabetic retinopathy: the influence of antiangiogenic therapy.
Laíns I; Figueira J; Santos AR; Baltar A; Costa M; Nunes S; Farinha C; Pinto R; Henriques J; Silva R
Retina; 2014 Jun; 34(6):1199-207. PubMed ID: 24280668
[TBL] [Abstract][Full Text] [Related]
30. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema.
Matsuda S; Tam T; Singh RP; Kaiser PK; Petkovsek D; Carneiro G; Zanella MT; Ehlers JP
J Diabetes Complications; 2014; 28(2):166-70. PubMed ID: 24374138
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
32. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
33. Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study.
Ting DS; Ng WY; Ng SR; Tan SP; Yeo IY; Mathur R; Chan CM; Tan AC; Tan GS; Wong TY; Cheung CM
Am J Ophthalmol; 2016 Apr; 164():128-36.e1. PubMed ID: 26743619
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
35. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
36. Initial macular thickness and response to treatment in diabetic macular edema.
Soheilian M; Ramezani A; Yaseri M; Mirdehghan SA; Obudi A; Bijanzadeh B
Retina; 2011 Sep; 31(8):1564-73. PubMed ID: 21451442
[TBL] [Abstract][Full Text] [Related]
37. Enhanced depth imaging optical coherence tomography of the choroid in central retinal vein occlusion.
Tsuiki E; Suzuma K; Ueki R; Maekawa Y; Kitaoka T
Am J Ophthalmol; 2013 Sep; 156(3):543-547.e1. PubMed ID: 23688711
[TBL] [Abstract][Full Text] [Related]
38. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
40. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
